People on the Move
Francois Nader
Trevena Inc., a drug developer working with G-protein coupled receptor (GPCR) biased ligands, announced Francois Nader has joined its board of directors. Nader has been president and CEO of NPS Pharmaceuticals since 2008.
“Dr Nader is a biopharmaceutical industry veteran with a track record of advancing novel therapies from the clinic to the market," said Trevena’s CEO Maxine Gowen.
"His guidance and perspective on clinical, regulatory, and corporate strategy will be of tremendous benefit to Trevena as we advance our clinical pipeline, including TRV027 for acute heart failure and TRV130 for postoperative pain.
“We also look forward to his insight as we work to leverage the potential of our novel biased-ligand technology platform to expand our pipeline and support long-term growth."
